Outlook Therapeutics: Poised to Capitalize on Market Opportunities with LYTENAVA Amidst Industry Shifts
BTIG analyst Julian Harrison reiterated a Buy rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of ...
Pharmabiz5d
Cullinan Therapeutics gets US FDA clearance to proceed phase 1 trial of CLN-978 in patients with moderate to severe systemic lupus erythematosus
Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...
marketinference5d
Cullinan Therapeutics FDA Cleared for CLN-978
The primary objective is to evaluate the safety of CLN-978 for the treatment of active moderate to severe SLE, with secondary ...
Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study
Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said the ...
manilatimes6d
The Devon Group Launches the Clear Communicator Awards to Celebrate Excellence in HR Tech Marketing
Inaugural Program Will Recognize Marketing Campaigns, Event Strategies and Brand Awareness Initiatives ...
Cullinan Management: Promising Investment in CD19-Targeted Immunotherapy with Strong Stock Performance
Cullinan Management (CGEM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit ...